ReviewAlzheimer's & dementia : the journal of the Alzheimer's Association2026
Menopausal insomnia as a modifiable node of dementia risk: Mechanistic insights and intervention strategies.
Review in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The menopausal transition is often accompanied by neuropsychiatric symptoms such as sleep disturbances, representing a modifiable window for Alzheimer's disease and related dementia (ADRD) prevention. Current preventive strategies fail to address the heterogeneity of postmenopausal cognitive trajectories, where some women exhibit rapid cognitive decline while others maintain sustained resilience over decades. This divergence suggests distinct neuroendocrine mechanisms that remain poorly understood and untargeted by current interventions. Given estrogen's fundamental role in brain function, compensatory enhancement of brain-local estrogen synthesis supports synaptic integrity and promotes resilience against neurodegeneration. Parvalbumin-positive (PV) interneurons enhance synaptic activity-dependent brain-derived estradiol (BDE2) synthesis in a sex-specific manner. Non-invasive gamma-rhythmic neuromodulation targeting PV interneurons via closed-loop protocols delivered during sleep can maximize therapeutic efficacy while minimizing off-target effects. A dual-cohort, parallel-group trial using neuronal pentraxin-2 (NPTX2) as a surrogate endpoint holds promise for assessing the efficacy of ADRD prevention and risk reduction in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.